Avastin, which prevents blood-vessel growth, is used to treat both wet age-related macular degeneration in the eye and for cancer.
The VA decision comes after FDA advisers rejected using the drug in breast cancer because of the risk of deadly bleeding. Also, macular degeneration patients at a VA facility in Los Angeles were blinded after being injected with the drug.
Related Articles on Avastin:
Four Patients Become Victims of Contaminated Shots at Tennessee VA Facility
Five More Patients Blinded by Drug in Los Angeles VA Hospital
FDA: Repackaged Avastin Caused Eye Infections in Florida
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
